北交所市场点评：缩量走弱，持续看好中长期趋势

Investment Rating - The report maintains a positive outlook on the long-term trend of the industry despite short-term fluctuations in the market [3]. Core Insights - The North Exchange A-share trading volume reached 22.95 billion yuan on November 4, a decrease of 3.08 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1528.79, down 2.45% [9][14]. - A total of 281 companies were listed on the North Exchange, with 34 stocks rising, 5 remaining flat, and 242 declining on the same day [16]. - The report highlights a significant adjustment in the pharmaceutical and robotics sectors due to decreased market risk appetite and profit-taking pressures [3]. - Positive signals include the steady advancement of the North Exchange's "14th Five-Year Plan" and the regulatory body's commitment to expedite the launch of the North Exchange 50 ETF, which is expected to enhance market liquidity and stability [3]. Summary by Sections Market Review - On November 4, the North Exchange A-share trading volume was 22.95 billion yuan, down 3.08 billion yuan from the previous day, with the North Exchange 50 Index closing at 1528.79, a decrease of 2.45% [9][14]. - The North Exchange specialized index closed at 2570.99, down 2.62% [9]. Stock Performance - Among the 281 companies, 34 saw an increase, 5 remained unchanged, and 242 experienced a decline [16]. - The top five gainers included: - Luqiao Information (10.8%) - Rongyi Precision (10.5%) - Tianma New Materials (8.4%) - Kerun Intelligent Control (8.3%) - Digital Human (8.2%) [16]. - The top five decliners included: - Danna Biology (-16.7%) - Kait Special (-6.8%) - Deer Chemical (-5.9%) - Haidar (-5.6%) - Yuanhang Precision (-5.6%) [16]. Important News - The National Health Commission issued a document supporting AI in healthcare, emphasizing grassroots applications, which may accelerate the entry of intelligent therapy products into clinical settings [3]. Investment Recommendations - The report suggests that despite short-term market pressures, investors should focus on structural opportunities, particularly in technology growth sectors aligned with national strategic directions, such as semiconductors, AI applications, biomedicine, and new materials [3].